PTC Therapeutics, Inc.

PTCT

US69366J2006

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-19 pm EDT			5-day change	1st Jan Change
25.32 ^USD	+2.55%		-4.16%	-8.13%

Mar. 28	PTC Therapeutics Seeks EMA Marketing Authorization for Sepiapterin for Phenylketonuria Treatment	MT
Mar. 28	PTC Therapeutics, Inc. Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA	CI

PTC Therapeutics, Inc. Reaffirms Revenue Guidance for the Full Year 2022

February 22, 2022 at 04:06 pm EST

PTC Therapeutics, Inc. reaffirms revenue guidance for the full year 2022. For the period the company expects the total revenue to be between $700 and $750 million.

Latest news about PTC Therapeutics, Inc.

PTC Therapeutics Seeks EMA Marketing Authorization for Sepiapterin for Phenylketonuria Treatment	Mar. 28	MT
PTC Therapeutics, Inc. Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA	Mar. 28	CI
ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza? as a Treatment for AADC Deficiency	Mar. 19	CI
Transcript : PTC Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 04:05 PM	Mar. 12
Transcript : PTC Therapeutics, Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-04-2024 01:30 PM	Mar. 04
PTC Therapeutics Shares Jump Following Q4 Results	Mar. 01	MT
TD Cowen Cuts Price Target on PTC Therapeutics to $30 From $32, Maintains Market Perform Rating	Mar. 01	MT
RBC Raises Price Target on PTC Therapeutics to $28 From $22, Keeps Sector Perform Rating	Mar. 01	MT
PTC Therapeutics Q4 Loss Narrows, Sales Up; Sets Guidance; Shares Slump After-Hours	Feb. 29	MT
PTC Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Transcript : PTC Therapeutics, Inc., Q4 2023 Earnings Call, Feb 29, 2024	Feb. 29
PTC Therapeutics, Inc. Provides Earnings Guidance for the Year 2024	Feb. 29	CI
Earnings Flash (PTCT) PTC THERAPEUTICS Posts Q4 Revenue $307.1M, vs. Street Est of $317.9M	Feb. 29	MT
PTC Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 29	CI
Sector Update: Health Care Stocks Higher Friday Afternoon	Jan. 26	MT
Cantor Fitzgerald Cuts PTC Therapeutics' Price Target to $45 From $51, Keeps Overweight Rating	Jan. 26	MT
Global markets live: LVMH, Intel, Tesla, Salesforce, Eli Lilly...	Jan. 26
Inflation is just the icing on the cake	Jan. 26
Sector Update: Health Care Stocks Mixed Premarket Friday	Jan. 26	MT
Sector Update: Health Care	Jan. 26	MT
RBC Cuts Price Target on PTC Therapeutics to $22 From $27 Amid Negative Opinion on Translarna From European Medicines Agency Committee; Sector Perform Kept	Jan. 26	MT
North American Morning Briefing : Intel Drags Down Chip Sector	Jan. 26	DJ
Stocks to Watch : Intel, PTC Therapeutics, KLA	Jan. 25	DJ
PTC Therapeutics' Muscle Disorder Drug Gets Negative Opinion From European Medicines Agency	Jan. 25	MT
Europe to withdraw PTC Therapeutics' rare muscle disorder drug	Jan. 25	RE

PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The Company has a diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).

Sector

Biotechnology & Medical Research

Calendar

2024-04-24 - Q1 2024 Earnings Release

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for PTC Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

24.69 USD

Average target price

29.17 USD

Spread / Average Target

+18.13%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
PTC THERAPEUTICS, INC.	-8.13%	1.89B
VERTEX PHARMACEUTICALS INCORPORATED	-3.10%	102B
REGENERON PHARMACEUTICALS, INC.	+2.11%	96.07B
ARGENX SE	-1.80%	21.66B
BIONTECH SE	-17.75%	20.77B
GENMAB A/S	-6.91%	18.53B
WUXI APPTEC CO., LTD.	-42.00%	16.91B
BEIGENE, LTD.	-28.19%	13.79B
NEUROCRINE BIOSCIENCES, INC.	+0.18%	13.33B
SAREPTA THERAPEUTICS, INC.	+19.90%	10.94B

Bio Therapeutic Drugs